HIV Prevention Clinical Trial
— IMARAVerified date | April 2019 |
Source | University of Illinois at Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study has three specific aims:
1. To conduct a 2-arm randomized controlled trial comparing IMARA to a family-based health
program (FUELTM). The investigators will:
a. Randomly assign 300 14-18 year-old AA or black girls and their primary female
caregivers to IMARA (N=150) or FUELTM (N=150). Women and girls will be recruited four
ways: 1) from mental health clinics using clinic liaisons, 2) flyers will be posted in
clinic recruitment sites and other agencies instructing interested families to call our
recruiter, 3) IMARA participants will hand flyers to interested women and girls they
know, and 4) COIP field station staff will pass out flyers and recruit interested women
and girls at the field stations and in the community. Investigators will examine the
effects of IMARA on women and girls' sexual behavior at 6- and 12-months.
2. To evaluate the impact of IMARA on theoretical mediators posited by the Theory of Gender
and Power and the Social-Personal framework associated with AA women and girls' risky
sex. Investigators will:
1. Assess changes in women and girls' Individual Attributes (HIV/AIDS knowledge,
attitudes, and beliefs, mental health/emotion regulation, ethnic identity); Peer
and Partner Processes (partner characteristics, relationship power dynamics, peer
influences, partner communication); and Family Context (mother-daughter
relationship and communication, parental monitoring) at baseline and follow-ups.
2. Evaluate mediation and moderation of theoretical mechanisms on women and girls'
sexual behavior.
3. To assess the impact of IMARA compared to FUELTM on sexually transmitted infections
(STIs). Investigators will:
1. Test women and girls' urine for three common STIs at baseline and 12-month follow
up.
2. Explore linkages between biological outcomes and targeted mediators and moderators
of change.
Status | Completed |
Enrollment | 514 |
Est. completion date | January 31, 2018 |
Est. primary completion date | January 31, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 14 Years and older |
Eligibility |
Inclusion Criteria: - Adolescent girls between 14-18 years of age, African American or Black. - Women who are primary female caregivers and self-identify as African American or Black, and are over the age of 18. - Women and daughters must agree to participate as a dyad. Exclusion Criteria: - If either participant is unable to understand the consent/assent process, do not speak English, are actively psychotic or severely mentally ill, or girls do not live with participating female caregiver. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Illinois at Chicago | Rush University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Risky Sexual Behavior | The AIDS-Risk Behavior Assessment (ARBA) is a computer-assisted interview of sexual behavior and drug use. The ARBA was derived from five established measures used in large-scale studies to examine HIV/AIDS-risk in youth and adults. The ARBA assesses substance use, sexual behavior, and needle use. Investigators will assess mothers and daughters' condom use, sex with high-risk partners, sex while using drugs/alcohol, number of partners, sexual debut -- and relative frequency and count-based indicators. | From Baseline to 6 month followup | |
Primary | Change in Incident STI infection | Investigators will measure women's and girls' STIs using biological endpoints (yes/no) to evaluate intervention effects. Investigators will screen urine for three sexually transmitted pathogens at baseline and 12- month follow up; N. gonorrhoeae, C. trachomatis, and T.vaginalis. Investigators will use nucleic acid amplification technologies (NAAT) for STI testing. | From Baseline to 12 month followup | |
Primary | Change in Risky Sexual Behavior | The AIDS-Risk Behavior Assessment (ARBA) is a computer-assisted interview of sexual behavior and drug use. The ARBA was derived from five established measures used in large-scale studies to examine HIV/AIDS-risk in youth and adults. The ARBA assesses substance use, sexual behavior, and needle use. Investigators will assess mothers and daughters' condom use, sex with high-risk partners, sex while using drugs/alcohol, number of partners, sexual debut -- and relative frequency and count-based indicators. | From Baseline to 12 month followup | |
Primary | Change in Peer and Partner Processes | Investigators will measure changes in women and girls' Peer and Partner Processes such as partner characteristics, relationship power dynamics, peer influences, and partner communication. | From Baseline to 6 month followup | |
Primary | Change in Peer and Partner Processes | Investigators will measure changes in women and girls' Peer and Partner Processes such as partner characteristics, relationship power dynamics, peer influences, and partner communication. | From Baseline to 12 month followup | |
Primary | Change in Individual Attributes | Investigators will measure changes in women and girls' Individual Attributes such as HIV/AIDS knowledge, attitudes, and beliefs, mental health/emotion regulation, and ethnic identity. | From Baseline to 6 month followup | |
Primary | Change in Individual Attributes | Investigators will measure changes in women and girls' Individual Attributes such as HIV/AIDS knowledge, attitudes, and beliefs, mental health/emotion regulation, and ethnic identity. | From Baseline to 12 month followup | |
Primary | Change in Family Context | Investigators will measure changes in women and girls' Individual Attributes such as Family Context (mother-daughter relationship and communication, and parental monitoring) | From Baseline to 6 month followup | |
Primary | Change in Family Context | Investigators will measure changes in women and girls' Individual Attributes such as Family Context (mother-daughter relationship and communication, and parental monitoring) | From Baseline to 12 month followup |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03411577 -
Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program
|
N/A | |
Active, not recruiting |
NCT03112369 -
Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use
|
N/A | |
Not yet recruiting |
NCT03642314 -
HIV Self-testing in Implementation PrEP Study
|
N/A | |
Completed |
NCT01810315 -
Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity
|
Phase 1 | |
Completed |
NCT00984971 -
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
|
Phase 1 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Active, not recruiting |
NCT03255915 -
PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)
|
Early Phase 1 | |
Completed |
NCT05037513 -
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
|
N/A | |
Recruiting |
NCT05087680 -
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
|
N/A | |
Recruiting |
NCT05804461 -
Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico
|
N/A | |
Completed |
NCT03148171 -
Project WERK (Wellness Encouragement Respect Kinship)
|
N/A | |
Completed |
NCT04791007 -
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
|
Early Phase 1 | |
Recruiting |
NCT05412433 -
Clinic-based HIV Identification and Prevention Project Using Electronic Resources
|
N/A | |
Active, not recruiting |
NCT03977181 -
The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms
|
N/A | |
Recruiting |
NCT05165745 -
Stick2PrEP Cisgender Women and Trans Individuals
|
N/A | |
Completed |
NCT03719053 -
Single Dose Truvada Study
|
Phase 1 | |
Recruiting |
NCT03856580 -
Long-acting Biomedical HIV Prevention in Transgender Women
|
N/A | |
Completed |
NCT02750540 -
Optimization of a Tenofovir Enema for HIV Prevention
|
Phase 1 | |
Completed |
NCT01386294 -
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
|
Phase 3 | |
Completed |
NCT00993811 -
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
|
Phase 1 |